Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 6/20 | 0.56 |
| ▸ | CCNH | P51946 | 6/20 | 0.56 |
| ▸ | PIP4K2A | P48426 | 3/20 | 0.48 |
| ▸ | PIP4K2B | P78356 | 3/20 | 0.48 |
| ▸ | BTK | Q06187 | 7/20 | 0.45 |
| ▸ | ITK | Q08881 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | CD69 | Q07108 | 1/20 | 0.42 |
| ▸ | BLK | P51451 | 1/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20225392 | 0.94 | CDK7 (0.52) | CDK7CCNHPIP4K2APIP4K2BBTK | |
| SCHEMBL20225384 | 0.88 | CDK7 (0.75) | CDK7CCNHPIP4K2APIP4K2B | |
| SCHEMBL18313107 | 0.84 | CDK7 (0.76) | CDK7CCNHPIP4K2APIP4K2BBTK | |
| SCHEMBL14979755 | 0.82 | PDGFRA (0.59) | CDK7CCNHPIP4K2APIP4K2BBTK | |
| SCHEMBL18346307 | 0.81 | CDK7 (0.43) | CDK7CCNHBTKITKEGFR | |
| SCHEMBL20228952 | 0.78 | CDK7 (0.63) | CDK7CCNHPIP4K2APIP4K2B | |
| SCHEMBL14979754 | 0.76 | BTK (0.56) | CDK7CCNHPIP4K2APIP4K2BBTK | |
| SCHEMBL20228962 | 0.75 | CDK7 (0.79) | CDK7CCNHPIP4K2APIP4K2B | |
| SCHEMBL18346366 | 0.74 | EGFR (0.55) | CDK7CCNHPIP4K2APIP4K2BBTK | |
| SCHEMBL22606038 | 0.74 | CDK7 (0.68) | CDK7CCNHBTKEGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342798-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10342798-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180369243-A9 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-12-27 | — | — | US | disclosed |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| EP-3313529-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | Dana Farber Cancer Institute, Inc. (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210291-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369243-A9 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | CDK3, CDK14, CDK1 | CDK7 5/4885CCNH 65/4885PIP4K2A 16/4885 |
| US-10342798-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | CDK3, CDK14, CDK1 | CDK7 5/4885CCNH 65/4885PIP4K2A 16/4885 |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | CDK3, CDK14, CDK1 | CDK7 5/4885CCNH 65/4885PIP4K2A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.